Archive · 12 Aug 2025
Biogen Explores Combining Alzheimer's and Obesity Drugs
Biogen's CEO believes combining drugs for Alzheimer's and obesity could be beneficial.
Novo Nordisk is testing if weight-loss drugs can help people with early Alzheimer's, and the results are expected later this year.
Being overweight increases the risk of Alzheimer's, so combining the drugs might help.
Biogen's current Alzheimer's drug, Leqembi, faces competition.
Biogen is also investing more in their manufacturing in North Carolina to produce Leqembi.
The CEO is unsure if the Novo trials will succeed due to prior failures in Alzheimer's drug development.
Biogen CEO sees potential in combining Alzheimer's and obesity drugs.
Novo Nordisk is testing weight-loss drugs for early Alzheimer's; results expected this year.
Being overweight is a risk factor for Alzheimer's, according to the CEO.
Biogen's Leqembi faces competition from Eli Lilly's Alzheimer's drug.
Biogen plans to invest $2 billion in its North Carolina manufacturing facility.
- Who
- Biogen's CEO Chris Viehbacher and Novo Nordisk are involved in Alzheimer's drug research.
- What
- Biogen is exploring combining Alzheimer's and obesity drugs. Novo Nordisk is conducting trials of weight loss drugs for Alzheimer's.
- When
- Results of Novo Nordisk's trial are expected later this year.
- Where
- Biogen manufactures Leqembi in Switzerland and North Carolina.
- Why
- To potentially improve Alzheimer's treatment by targeting multiple mechanisms of action.
Skepticism
Potential for Synergy
Drug Efficacy
Skepticism
Doubts exist about the efficacy of combining the drugs based on past failures and a general lack of evidence in favor.
Potential for Synergy
Potential for therapeutic synergy; if Novo’s study works, combining the drugs might provide further benefit for patients.
- Company
- Biogen
- Drug
- Leqembi
- Potential Partner
- Novo Nordisk
- Competitor
- Eli Lilly & Co.
- Biogen Investment
- $2 billion